Mast cells are important not only in allergic reactions, but also in inflammation and are involved in a variety of responses including the immediate release of potent inflammatory mediators after activation by cross-linking of FCERI molecules. Prostaglandin D2 (PGD2) is a major cyclooxygenase metabolite of arachidonic acid produced by mast cells and it is released following allergen challenge in allergic diseases. IL-33 is an iflammatory cytokine which is critically involved in the regulation of in vitro and in vivo cyclooxygenase production, providing a potential therapeutic target for inflammatory disorders. In this study, using human derived umbelical cord blood mast cells, we show that IL-33 (50 ng/ml), and calcium ionophore A 23187 (0.5 f.1g/ml), compound 48/80 (10-5 M) or anti-IgE (10 ug/rnl), enhaced the production ofPGD2 and this effect was inhibited by indomethacin. However, IL-33 was unable to induce tryptase release in these cells. These effects confirm the inflammatory property of IL-33 by stimulating PGD2 but not tryptase in human mast cells. The inhibitory effect of this new cytokine may have a potential therapeutic response in allergic and inflammatory diseases.
It has been reported that IL-l beta, IL-18 or IL-33 induced phosphorylation of Erk, p38 and JNK in naive HDUCBMCs, and IL-33 or IL-l beta, but not IL-18, enhanced the survival of naive HDUCBMCs (30) (31) (32) (33) (34) . Prostaglandin D2, the major cyclooxygenase metabolite generated from immunologically and nonimmunologically stimulated mast cells, is thought to contribute to the pathogenesis of allergic diseases due to its various inflammatory effects (35) (36) (37) (38) .
The ability of mast cells to generate or release the vasoactive/spasmogenic mediators histamine, PGD2, sulfidopeptide leukotrienes, plate1etactivating factor and other factors is thought relevant to immediate broncho-spastic responses in association with mucus secretion and airway edema (39) (40) (41) . Using human-derived umbilical cord blood mast cell (HDUCBMC), it is pertinent therefore, to evaluate the effect of IL-33 on PGD2 generation in HDUCBMC cultures.
MATERIALS AND METHODS

Cells and materials
Reagents for cell culture were purchased from Sigma-Aldrich. HDUCBMC were cultured in Iscove's Modified Dulbecco's medium supplemented with 10% bovine calf serum, 1.2 mM monothioglycerol, 2 mM L-glutamine, 100 U/ml penicillin, 100 ug/ml streptomycin either in 25 ern-tissue culture plates or in six-well tissue culture plates (Costar). Cells were plated at a density of 0.2x I0 6 per ml taken from the 3-day-old culture grown under the same conditions. Cells were grown in an incubator in a 5% CO 2 and 95% O 2 at 37°C.
Human derived cord blood mast cell isolation, culture and treatment.
Umbilical cord blood was collected in tubes containing 10 U/ml heparin and diluted 1:2 with Dulbecco's phosphate buffered saline (DPBS) from GIBCO BRL (Life Technologies, Grand Island, NY) containing 2 mM ethylenediamine-tetra acetic acid (Sigma). Nonphagocytic mononuclear cells were separated by densitygradient centrifugation using Lymphocyte Separation Medium (LSM). The isolation of hematopoietic stem cells (CD34+) was performed by positive selection of CD34+/AC 133+ cells by magnetic associated cell sorting (MACS) using an AC 133+ cell isolation kit (Milltenyi Biotec, Auburn, CA). CD 133 expression is restricted to a subset of CD34 bright positive stem cells in human cord blood. Mast cells had been obtained by culturing cord blood mononuclear cells in the presence of SCF, IL-6. CD34+ cells were suspended in Iscove's Modified Dulbecco's Medium (IMDM; GIBCO BRL), supplemented with 100 ng/ml rhSCF, 50 ng/ml IL-6, 10% fetal bovine serum, 5x10-s M2-Mercaptoethanol, and I% penicillin-streptomycin (GIBCO BRL) for 12 to 16 weeks. During this culture period, the cells were washed with DPBS every week and resuspended using fresh complete culture medium. Mast cell viability was determined by trypan blue (0.3%) exclusion and observed under light and electron microscope. For sensitization, HDCBMCs were washed with DPBS and plain culture medium (without any growth factors) once in each and resuspended in serum-free complete culture medium, but without IL-6 supplementation. Cells (l x10 6 cells/ ml) were then incubated with human myeloma-IgE (2 ug/ml/Ifl? cells) at 37°C for 48 h in 24-well Falcon cell culture plates. These sensitized HDUCBMCs were used in all the experiments and treated for 12 h with IL-33, A23l87, 48/80 or anti-IgE.
Activation ofHCBMC with anti-IgE
Anti-Human IgE (DAKO Rabbit anti-Human IgE, Specific for Epsilon-chains. Code number A 0094; Lot no. 069. Edition 05.07.00) was used in this study at 10 ug/ml. For anti-IgE stimulation experiments, HDUCBMC (l0" cells/ml) were washed with Iscove's modified Dulbecco's medium and Tyrode's buffer, once in each, and passively sensitized by incubation with human myeloma IgE (2 Ilg/ mUI0 6 cells; Chemicon Inc.) for 48 h in culture medium at 37°C. Cells were then washed two times and resuspended in fresh culture medium. Cells were stimulated with anti-IgE (Dako) at 15 ug/ml in 96-well round bottom culture plates (l x 10"cells/ml in 200 /!l medium! sample) for 12 hat 3rC in 5% CO 2 ,
Immunoassaysfor tryptase
Tryptase was measured in the supernatants and cell pellets by UniCAP Tryptase Fluoroenzyme-immunoassay System (Phannacia Diagnostics AB, Uppsala, Sweden) as reported previously (Schwartz LB 1994). Briefly, anti-tryptase covalently coupled to ImmunoCAP® reacts with the tryptase in the specimen. After washing, enzyme-labeled antibodies against tryptase are added to form a complex. After incubation, unbound enzyme-antitryptase is washed away and the bound complex is then incubated with a developing agent. After stopping the reaction, the fluorescence of the eluate is measured in the Fluorof'ount" 96 microplate reader. The fluorescence is directly proportional to the concentration of tryptase in the sample. To evaluate the test results, the response for the samples is compared directly to the response of the standards. Tryptase was measured in the supernatants and cell pellets by fluoroenzyme-immunoassay (Pharmacia, Uppsala, Sweden). These peptides were measured in the supernatant and pellet to calculate percent release.
Tryptase release assay: For tryptase measurements, HDUCBMC were sensitized with human myeloma IgE for 48 h in culture medium and were then stimulated for different periods of time in Tyrode's buffer (133 mM NaCl, 4 mM KCI, 0.64 mM KHl04, 10 mM HEPES, I gil glucose, I mM CaCL z' 0.6 mM MgCl z and 0.03% human serum albumin, pH 7.2). Results were expressed in ng/l 0 6 cells/m!.
Determination ofcell viability
HDUCBMC were harvested, washed in PBS and centrifuged for 5 min at 400x g at room temperature. Cells were then resuspended in culture medium, 0.1% trypan blue solution was added for 5 min at room temperature and the cells were counted using a haemocytometer. Viability was 99%, expressed as percentage of cells which do not take up trypan blue.
Stimulation ofHDUCBMC
Calcium ionophore A23 I 87 (0.5 ug/ml), compound 48/80 (10. 5 M), anti-IgE (10 mg/ml) or IL-33 (50 ng/ml) at different dilutions were made directly in HDUCBMC culture medium. In separate tubes, in each experiment, cells were exposed to the vehicle alone, to determine non-specific release. HDUCBMC (Ix l G'cells/ml) in a six well tissue culture dish were washed with culture medium containing I mg/ml bovine serum albumin (BSA) and without Ca++ to reduce spontaneous secretion. They were then sensitized in the same medium for 30 min at 37°C with 2 ml of mouse monoclonal anti-DNP IgE (500 ng/ ml). After sensitization the cells were washed again and treated for 60 min at 37°C with 2 ml ofDNP-BSA (10 ng/ ml) in the same medium, but now supplemented with 0.5 mM calcium to permit secretion. Control samples without IgE were run simultaneously in the presence of 0.5 mM Ca'" and these values represented non-specific release. The cells were also activated for 12 h with calcium ionophore A23187 (0.5 ug/ml), compound 48/80 (10. 5 M), anti-IgE (10 mg/ml) or IL-33 (50 ng/ml) and PGD2 was calculated.
ELISAfor PGD2
All the experiments were performed with HDCBMC obtained over about 8 weeks. Briefly, the cells were cultured for 12 h with and without reagents to be tested with anti-IgE (10 mg/ml), 48/80 (10-5 M), A23187 (0.5 Ilg/ ml), and IL-33 (50 ng/ml). After incubation, the cells were centrifuged at 4000 rpm. for 8 min. The supernatants were removed and stored at -20°C. The levels of the PGD z were determined by a PGDz-specific ELISA. The kit is composed of 96 determinations and the assays were performed according to the manufacturer's instructions. The ELISA reader was set at 405 nm absorbance and all the samples were read after I h after addition of stop solution. The wells were protected from light and incubated at room temperature.
The antiserum anti-PGl), (rabbit) was reconstituted in phosphate buffer containing BSA and sodium azide, as recommended by the manufacturer. PGD z alkaline phosphatase conjugate was supplied ready to use in bicarbonate buffer containing 0.1% BSA, magnesium chloride and sodium azide at pH 9.8 and stored at 4°C. PGD2 was determined in cell-free supernatants with commercial ELISA kit (R&D Systems, Minneapolis, MN) according to the manufacturer's directions (sensitivity of the assay, 3 pg/ml).
Statistical analysis
All assays were performed in triplicate. The results were expressed as mean ± SD. Data from three different experiments were combined and reported as the mean ± SD. Student's r-test for independent means was used to provide statistical analyses (p>0.05 was considered as not significant). Comparisons were made using ANOVA.
RESULTS
Prostaglandin D2 secretion from purified HDUCBMC
The release of prostaglandin D2, from preparations of purified HDCBMC was determined. The production of prostanoid PGD2 was examined after mast cell activation. PGD2 was the prostanoid produced after stimulation of human derived umbilical cord blood mast cells with the IL-33 (50 ng/ml), calcium ionophore A 23187 (0.5 ug/ml), compound 48/80 (10-5 M) or anti-IgE (10 ug/ml), The production of PGD2 was apparent after 12 h (Table I) and was still detectble after 48 h (data not shown).
The principal cyclooxygenase products after 12 h was PGD2; while other arachidonic acid compounds appared if any in much lower concentrations (data not shown). Indomethacin (10-6 M) markedly inhibited the IL-33 (50 ng/ml), calcium ionophore A 23187 (0.5 ug/ml), compound 48/80 (10. 5 M) or anti-IgE (10 ug/ml) induced release of PGD2 from HDCBMC and completely suppressed evoked PGD2 synthesis without evident effect on histamine release (data not shown), suggesting that the release of histamine in this model is not dependent on Table I . PGD2 production from HDUCBMC (106 cells/ml) following the addition or not of IL-33 (50 ng/ml) prostaglandin production. The ability of the cells to secrete PG02 appears as a cytochemical marker of the in vitro mast cells.
Tryptase released/rom HDUCBMC HOUCBMCs have tryptase containing granules and receptors for IgE. In this study HOUCBMC were cultured with IL-33 (50 ng/ml) and a classic specific secretagogue anti-IgE, or a non-specific compounds such as calcium ionophore A23187 (0.5 ug/ml) or compound 48/80 (l0-5 M). Table II shows in three representative experiments the release of tryptase following HOUCBMC treatment and incubated for 60 min with or without IL-33, C48/80, anti-IgE (l0 ug/ml) and A23l87. Anti-IgE, calcium ionophore A23l87 (0.5 ug/ml) or compound 48/80 (l0-5 M) strongly stimulated tryptase on HOCBMC; while IL-33 was unable to do so.
DISCUSSION
Mast cells play a key role in the induction of allergic disorders, through the release of mediators including histamine, arachidonate products, proteases and several cytokines, which are found in relatively high quantities in these cells (42) (43) (44) (45) (46) . When activated by diverse stimuli, mast cells mobilize arachidonic acid through cytosolic phospholipase A2, and rapidly generate both prostaglandin 02 (47) (48) (49) (50) (51) . IL-33 induces biological effects on mast cells and T cells through its receptor IL-33Rf3-chain and may have pro-inflammatory potential effects similar to the cytokines from the same family (52) (53) (54) (55) (56) . IL-33 is found to be highly expressed in high endothelial venules, tonsils, lymph nodes, and Peyer's patches, in vessels from inflammed tissues, in the intestine of patients with Crohn's disease, and in the synovium (50 nglml) and the corresponding samples treated with calcium ionophore (A23187) (0.5 ug/ml), C48180 (10-5 M) or anti-lgE (10 ug/ml) .
(pg/ml) of patients with rheumatoid arthritis (57) (58) (59) (60) (61) . IL-33 is known to enhance experimental allergic inflammation by directly stimulation mast cells to produce inflammatory cytokines (62) (63) (64) (65) . Therefore, the mast cell is known as a conductor cell in allergic inflammation (66) (67) . Prostaglandin such as PGD2 is the major prostanoid secreted from the activated mast cell and is an important mediator in the pathogenesis of allergy (68) (69) (70) (71) (72) (73) . However, the direct effect of IL-33 on PGD2 generation by human mast cells is not known. Here, in this study, we found that IL-33 along with the physiological stimulator anti-IgE or with non-physiological compound A23187 or C48/80, strongly stimulated the production of PGD 2 in HDUCBMC. The stimulatory effect PGD 2 release was completely blocked by a non steroidal anti-inflammatory drug such as indomethacin. We also studied the effect of IL-33 on tryptase release by HDUCBMC and found that IL-33 did not increased the production of tryptase; while anti-IgE, A23l87 or C48/80 had a strong stimulator effect. These results suggest that IL-33 may play an important role in inflammatory diseases by activation PGD2 an arachidonic acid product released from mast cells. These results also indicated that IL-33 may be critically involved in regulation of cyclooxygenase production in vitro and probably in vivo, providing a potential therapeutic target for inflammatory disorders.
Our study shows that IL-33 activated HDUCBMCs can synthesize significant quantities of PGD2 which may be important in anaphylactic reactions. Prostaglandin D2 produced by mast cells in acute allergic reactions in vivo may contribute to the inflammatory reaction, either directly or in synergism with other mediators. The findings from these in vitro studies suggest that PGD2 secreted from activated mast cells after IL-33 treatment, may be involved in the formation and/or maintenance of allergic inflammation through its dual receptor systems without involving the activation of tryptase system.
PGD2 is the major cyclooxygenase product released from sensitized human lung and bronchoalveolar lavage mast cells, which possesses a myriad of biological actions relevant to the pathogenesis of asthma (74) (75) (76) (77) (78) (79) . Thus, modulation of the effects of products of arachidonic acid metabolism by IL-33 may provide a new and more specific treatment for asthma and allergy (80) (81) (82) (83) (84) (85) .
The localization of the arachidonic acid cascade to the secretory granule explains why the production of eicosanoids is so intimately tied to the process of granule exocytosis.
A significant number oftherapeutic approaches for allergies have been designed based on antagonising specific mediators released from mast cells and on selectively inhibiting the activation of these cells (86) (87) (88) (89) . Here, since IL-33 is a strong stimulator of PGD2 in human mast cells, the inhibition effect of this new cytokine may have a potential therapeutic response in allergic and inflammatory diseases.
